Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staloral Birch in Birch Pollen-Induced Rhinoconjunctivitis
NCT01731249Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Nov 2010
- Primary completion
- Jul 2012
- Modality
- Allergy Immunotherapy
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing Staloral Birch with Placebo (2 arms). Primary endpoint: Average Adjusted Symptom Score at Year 2. Started Nov 2010; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01731249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731249.